Alkermes (ALKS) Posts Better-Than-Expected Q2 Results; FDA Approval for Vivitrol; Lowers FY10 Sales Forecast

November 4, 2010 4:04 PM

Alkermes (Nasdaq: ALKS) reports Q2 loss of $0.01, 14 cents better ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found